Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.

<h4>Background</h4>There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French wo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emilie Cordina-Duverger, Thérèse Truong, Antoinette Anger, Marie Sanchez, Patrick Arveux, Pierre Kerbrat, Pascal Guénel
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c359b81233b8480fac01f06e907abfb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c359b81233b8480fac01f06e907abfb1
record_format	dspace
spelling	oai:doaj.org-article:c359b81233b8480fac01f06e907abfb12021-11-18T08:48:46ZRisk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.1932-620310.1371/journal.pone.0078016https://doaj.org/article/c359b81233b8480fac01f06e907abfb12013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24223752/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French women. Progestagen constituents, regimen (continuous or sequential treatment by the progestagen), and time interval between onset of menopause and start of MHT were examined.<h4>Methods</h4>We conducted a population-based case-control study in France in 1555 menopausal women (739 cases and 816 controls). Detailed information on MHT use was obtained during in-person interviews. Odds ratios and 95% confidence interval adjusted for breast cancer risk factors were calculated.<h4>Results</h4>We found that breast cancer risk differed by type of progestagen among current users of EP therapies. No increased risk was apparent among EP therapy users treated with natural micronized progesterone. Among users of EP therapy containing a synthetic progestin, the odds ratio was 1.57 (0.99-2.49) for progesterone-derived and 3.35 (1.07-10.4) for testosterone-derived progestagen. Women with continuous regimen were at greater risk than women treated sequentially, but regimen and type of progestagen could not be investigated independently, as almost all EP combinations containing a testosterone-derivative were administered continuously and vice-versa. Tibolone was also associated with an increased risk of breast cancer. Early users of MHT after onset of menopause were at greater risk than users who delayed treatment.<h4>Conclusion</h4>This study confirms differential effects on breast cancer risk of progestagens and regimens specifically used in France. Formulation of EP therapies containing natural progesterone, frequently prescribed in France, was not associated with increased risk of breast cancer but may poorly protect against endometrial cancer.Emilie Cordina-DuvergerThérèse TruongAntoinette AngerMarie SanchezPatrick ArveuxPierre KerbratPascal GuénelPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e78016 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Emilie Cordina-Duverger Thérèse Truong Antoinette Anger Marie Sanchez Patrick Arveux Pierre Kerbrat Pascal Guénel Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
description	<h4>Background</h4>There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French women. Progestagen constituents, regimen (continuous or sequential treatment by the progestagen), and time interval between onset of menopause and start of MHT were examined.<h4>Methods</h4>We conducted a population-based case-control study in France in 1555 menopausal women (739 cases and 816 controls). Detailed information on MHT use was obtained during in-person interviews. Odds ratios and 95% confidence interval adjusted for breast cancer risk factors were calculated.<h4>Results</h4>We found that breast cancer risk differed by type of progestagen among current users of EP therapies. No increased risk was apparent among EP therapy users treated with natural micronized progesterone. Among users of EP therapy containing a synthetic progestin, the odds ratio was 1.57 (0.99-2.49) for progesterone-derived and 3.35 (1.07-10.4) for testosterone-derived progestagen. Women with continuous regimen were at greater risk than women treated sequentially, but regimen and type of progestagen could not be investigated independently, as almost all EP combinations containing a testosterone-derivative were administered continuously and vice-versa. Tibolone was also associated with an increased risk of breast cancer. Early users of MHT after onset of menopause were at greater risk than users who delayed treatment.<h4>Conclusion</h4>This study confirms differential effects on breast cancer risk of progestagens and regimens specifically used in France. Formulation of EP therapies containing natural progesterone, frequently prescribed in France, was not associated with increased risk of breast cancer but may poorly protect against endometrial cancer.
format	article
author	Emilie Cordina-Duverger Thérèse Truong Antoinette Anger Marie Sanchez Patrick Arveux Pierre Kerbrat Pascal Guénel
author_facet	Emilie Cordina-Duverger Thérèse Truong Antoinette Anger Marie Sanchez Patrick Arveux Pierre Kerbrat Pascal Guénel
author_sort	Emilie Cordina-Duverger
title	Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
title_short	Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
title_full	Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
title_fullStr	Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
title_full_unstemmed	Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
title_sort	risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in france.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/c359b81233b8480fac01f06e907abfb1
work_keys_str_mv	AT emiliecordinaduverger riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT theresetruong riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT antoinetteanger riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT mariesanchez riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT patrickarveux riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT pierrekerbrat riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance AT pascalguenel riskofbreastcancerbytypeofmenopausalhormonetherapyacasecontrolstudyamongpostmenopausalwomeninfrance
_version_	1718421286481297408

Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.

Ejemplares similares